Mallick U, Newbold K, Beasley M, Garcez K, Wadsley J, Johnson SJ et al.
Lancet 2025; 406: 52-62.
This study that included 504 patients with complete resection of low grade thyroid cancer did not benefit from additional radioiodine ablation. Five-year recurrence-free survival was similar: 96.3% ablation vs 97.9% in controls.
Comment: Conclusive trial showing radioiodine ablation is unnecessary in these patients.



.png)





.jpg)




